OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Rheumatology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
No benefit from adding MTX to ustekinumab	513
Bimekizumab effective across the axSpA spectrum	442
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	335
Genome-wide mutagenesis reported in systemic sclerosis	295
The role of the patient in rheumatology	263
Osteoarthritis as a systemic disease	222
Biological and clinical roles of IL-18 in inflammatory diseases	210
Rheumatic diseases on the rise	187
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	175
A role for TGFβ and EBV in MIS-C pathogenesis	174
Towards better management of sterile bone inflammation	164
New drug formulation reduces bone loss	158
To choose or not? The value of discrete-choice experiments in rheumatology	156
Urchin-like nanoparticles for miRNA therapy of OA	152
The value of comparative efficacy studies in informing rheumatology guidelines	147
2021 ACR guideline for JIA reflects changes in practice	147
The 2022 ACR vaccination guideline: a call-to-action	147
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	141
Inflammation across tissues: can shared cell biology help design smarter trials?	140
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	132
Down syndrome: insights into autoimmune mechanisms	132
MIS-C: myths have been debunked, but mysteries remain	127
Appraising the evolving landscape of protease inhibition in osteoarthritis	125
FOXP3 splice variant is associated with autoimmune disease	124
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	122

Low-dose glucocorticoids benefit seniors with RA	118
Guiding ILD management in systemic autoimmune rheumatic diseases	115
Co-trimoxazole reduces mortality in anti-MDA5-DM	115
Immune reset and immune retune: approaching cure?	110
Fibroblast TGFβ drives treatment-refractory RA	109
COPA syndrome spans multiple organs but is defined by STING in the lung	106
Wnt-induced IGF1 drives OA	105
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	105
A direct link between SARS-CoV-2 and bone loss	104
Author Correction: Proposals for the rheumatological use of JAK inhibitors	100
Calprotectin tracks tocilizumab-treated RA	99
Fumarate drives interferon release in systemic sclerosis monocytes	98
S100A4 inhibition targets fibrosis in SSc	96
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	92
Pain in systemic lupus erythematosus: emerging insights and paradigms	92
Low back pain is a growing concern	88
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	87
Rheumatology in the digital health era: status quo and quo vadis?	85
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	82
Rheumatic diseases and metabolism: where centre and periphery meet	79
Targeting the IVD clock to halt degeneration	76
Which DMARD for ICI-associated arthritis?	73
sCD13 role in arthritis mediated via bradykinin receptor	73
Macrophage-coated nanocarriers for gouty arthritis	72
Cell-free DNA fragmentation signatures link cancer and autoimmunity	71
Erosive cargo from synovial fibroblasts	67
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	65
A path towards personalized medicine for autoinflammatory and related diseases	65
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	65
Phase III trial of telitacicept in SLE	65
Insights into IVDD pathogenesis in 2024	64
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	63
CAR T cells induce drug-free SLE remission	61
ERAP1 and the return of the UPR in ankylosing spondylitis	57
Blocking CDK7 attenuates inflammatory arthritis	56
RA risk from occupational inhalation	56
Repolarizing macrophages using antagomirs	54
Improving the design of RCTs in non-radiographic axial spondyloarthritis	54
Fibroblast heterogeneity in 2025	53
A leading role for interferon as a treatment target in Sjögren syndrome	50
A critical view of WHO guidelines on management of low back pain	49
All fibroblasts are equal, but some are more equal than others	49
New refinements aim to optimize articular cartilage tissue engineering	47
Two sides of management recommendations for psoriatic arthritis	46
Reply to ‘Is cam morphology a cause of osteoarthritis?’	46
Platelets as drivers of immunothrombosis in rheumatic diseases	45
New developments in electronic health record analysis	45
TASL has a key role in SLE	45
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	44
Profiling joint tissues at single-cell resolution: advances and insights	44

APOE in fat pad and synovium contributes to knee OA	43
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	43
AhR promotes suppressor cell function in Sjögren syndrome	42
Piezo1 induces new bone formation in AS	42
CXCL5 effective in mouse model of SLE	41
Pathogenic antibodies target stromal antigens in RA	41
Treg cell-inducing nanoparticles show promise for treating OA	39
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	38
Unravelling the cellular mechanisms of VEXAS syndrome	38
Author Correction: Glycobiology of rheumatic diseases	34
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	34
Sex- and gender-based personalized medicine in rheumatology	33
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies	33
Metabolic masqueraders of paediatric and adult rheumatic diseases	33
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	33
Fertility, pregnancy and lactation in women with systemic lupus erythematosus	33
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	32
Shifting the SLE management paradigm: challenges and implications	31
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	31
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	30
STING-driven necroptosis linked to autoinflammatory disease	29
In vivo CAR-T cell engineering in refractory SLE	29
Location-specific treatment of chronic inflammatory joint disease	29
BiTE therapy for rheumatic diseases	28
Parathyroid hormone receptor agonists in the management of osteoporosis	28
Mechanisms and clinical implications of intervertebral disc calcification	28
Post-transcriptional checkpoints in autoimmunity	27
Critical appraisal of serum urate targets in the management of gout	26
Multi-omics reveals distinct MPA subtypes	26
FABP4 exacerbates RA	26
Adropin inhibits fibrosis in SSc	26
Detachment promotes RA synovial fibroblast survival and invasiveness	26
COVID-19 linked to rise in anti-MDA5 autoimmunity	25
State-of-the-art evidence in the treatment of systemic sclerosis	24
Engineered sialylated IgG1 Fc as a dose-sparing alternative to IVIG	24
Complement therapeutics are coming of age in rheumatology	24
Notch signalling mediates OA pain in mice	24
Citrulline immunity in RA: CD8+ T cells enter the scene	23
Busting the myth of methotrexate chronic hepatotoxicity	23
The potential contribution of in silico studies to improved treatment of osteoarthritis	23
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	23
Identifying fibromyalgia phenotypes based on psychological symptom burden	22
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	22
What rheumatology can learn from oncology: a patient’s perspective	22
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	22
Update on the pathophysiology and treatment of primary Sjögren syndrome	21
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	20
Treatment of non-systemic juvenile idiopathic arthritis	20
The immune health metric as an indicator of health and disease	19
Combination therapy for Behçet uveitis	18
Undiagnosed axSpA is prevalent in IBD	18
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	18
The PU.1– IL-9 axis in TH9 cells promotes RA	18
Bone-modifying drugs slow OA progression	17
More than a leaky gut: how gut priming shapes arthritis	17
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	17
Glycosylation switch in synovial fibroblasts promotes ECM degradation	16
UNC93B1 variants promote SLE via TLR activation	16
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	16
SIX1 and PAI-1 emerge as therapeutic targets in systemic sclerosis	16
Shedding light onto the immunometabolic effects of glucocorticoids	16
Primary care rheumatology: towards sustainable development in health	16
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	16
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	15
Reversal of inflammatory priming prevents arthritic flares	15
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	15
Advances in understanding preclinical rheumatoid arthritis and prospects for prevention	15
T cell differentiation in Sjögren syndrome is regulated by TOX	14
Paediatric glucocorticoid toxicity index: new possibilities in assessment	13
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	12
Disease stratification in GCA and PMR: state of the art and future perspectives	12
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	12
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	12
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	12